Comparative proteomic analysis of anti-cancer mechanism by periplocin treatment in lung cancer cells

Cellular Physiology and Biochemistry

Volumn 33, Issue 3, 2014, Pages 859-868

  Lu, Zejun ^a   Song, Qi ^b   Yang, Jinliang ^c   Zhao, Xiangfei ^a   Zhang, Xinhong ^a   Yang, Ping ^a   Kang, Jingbo ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Lung cancer; Periplocin; Proteome; Two demensional electrophoresis

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTINEOPLASTIC AGENT; ATP SYNTHASE ECTO ALPHA SUBUNIT; COFILIN 1; EARLY PREGNANCY FACTOR; HEAT SHOCK COGNATE 71; HEAT SHOCK PROTEIN; INITIATION FACTOR 5A; PERIPLOCIN; PROFILIN I; PROTEASOME SUBUNIT BETA TYPE 6; PROTEIN; RAN PROTEIN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 1; UNCLASSIFIED DRUG; HEAT SHOCK COGNATE PROTEIN 70; PROFILIN; PROTEASOME; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE ECTO ALPHA SUBUNIT; PROTEOME; SAPONIN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TRANSCRIPTION REGULATION; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; A549 CELL LINE; PLEIOTROPY; BIOSYNTHESIS; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

EUKARYOTA;

CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS; SAPONINS;

EID: 84897121368     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358658     Document Type: Article

References (33)

1. Yu Y, Xu X, Du Z, Shi M: Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials. Cancer Chemother Pharmacol 2012;69:1265-1275.
2. Wang S, Wu X, Tan M, Gong J, Tan W, Bian B, Chen M, Wang Y: Fighting fire with fire: poisonous Chinese herbal medicine for cancer therapy. J Ethnopharmacol 2012;140:33-45.
3. Newman RA, Yang P, Pawlus AD, Block KI: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008;8:36-49.
4. Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F, Kiss R: Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta 2007;1776:32-57.
5. Winnicka K, Bielawski K, Bielawska A, Surazyński A: Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells. Biol Pharm Bull 2008;31:1131-1140.
6. Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM: Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest New Drugs 2006;24:423-427.
7. Lu ZJ, Zhou Y, Song Q, Qin Z, Zhang H, Zhou YJ, Gou LT, Yang JL, Luo F: Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways. Cell Physiol Biochem 2010;26:609-618.
8. Lu ZJ, Liu SY, Yao YQ, Zhou YJ, Zhang S, Dai L, Tian HW, Zhou Y, Deng HX, Yang JL, Luo F: The effect of miR-7 on behavior and global protein expression in glioma cell lines. Electrophoresis 2011;32:3612-3620.
9. Lu ZJ, Song QF, Jiang SS, Song Q, Wang W, Zhang GH, Kan B, Chen LJ, Yang JL, Luo F, Qian ZY, Wei YQ, Gou LT: Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen.BMC Cancer 2009;9:16.
10. von Mering C, Jensen LJ, Kuhn M, Chaffron S, Doerks T, Krüger B, Snel B, Bork P: STRING 7-recent developments in the integration and prediction of protein interactions. Nucleic Acids Res 2007;35:D358-362.
11. Schoner W, Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007;293:C509-536.
12. Bagrov AY, Shapiro JI, Fedorova OV: Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 2009;61:9-38.
13. Egawa K, Kurihara Y, Ito T, Matsumoto M, Nose K: Induction of p16INK4a transcription and of cellular senescence by aclacinomycin-derivatives and cardiac glycosides. Biol Pharm Bull 2002;25:461-465.
14. Xie YS, Ren XL, Pan GX, Gao XM, Liu CX: The assessment of absorption of periplocin in situ via intestinal perfusion of rats by HPLC. Biomed Chromatogr 2008;22:196-201.
15. Du YY, Liu X, Shan BE: Periplocin extracted from cortex periplocae induces apoptosis of SW480 cells through inhibiting the Wnt/beta-catenin signaling pathway. Ai Zheng 2009;28:456-460.
16. Zhao L, Shan B, Du Y, Wang M, Liu L, Ren FZ: Periplocin from Cortex periplocae inhibits cell growth and down-regulates survivin and c-myc expression in colon cancer in vitro and in vivo via beta-catenin/TCF signaling. Oncol Rep 2010;24:375-383.
17. Champagne E, Martinez LO, Collet X, Barbaras R: Ecto-F1Fo ATP synthase/F1 ATPase: metabolic and immunological functions. Curr Opin Lipidol 2006;17:279-284.
18. Chi SL, Wahl ML, Mowery YM, Shan S, Mukhopadhyay S, Hilderbrand SC, Kenan DJ, Lipes BD, Johnson CE, Marusich MF, Capaldi RA, Dewhirst MW, Pizzo SV: Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. Cancer Res 2007;67:4716-4724.
19. Malaval C, Laffargue M, Barbaras R, Rolland C, Peres C, Champagne E, Perret B, Tercé F, Collet X, Martinez LO: RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes. Cell Signal 2009;21:120-127.
20. Vantourout P, Martinez LO, Fabre A, Collet X, Champagne E: Ecto-F1-ATPase and MHC-class I close association on cell membranes. Mol Immunol 2008;45:485-492.
21. Ruan Y, Wan M: An optimized procedure for solubilization, reduction, and transfer of human breast cancer membrane-enriched fraction by 2-DE. Electrophoresis 2007;28:3333-3340.
22. Huang TC, Chang HY, Hsu CH, Kuo WH, Chang KJ, Juan HF: Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J Proteome Res 2008;7:1433-1444.
23. Ma Z, Cao M, Liu Y, He Y, Wang Y, Yang C, Wang W, Du Y, Zhou M, Gao F: Mitochondrial F1Fo-ATP synthase translocates to cell surface in hepatocytes and has high activity in tumor-like acidic and hypoxic environment. Acta Biochim Biophys Sin 2010;42:530-537.
24. Pan J, Sun LC, Tao YF, Zhou Z, Du XL, Peng L, Feng X, Wang J, Li YP, Liu L, Wu SY, Zhang YL, Hu SY, Zhao WL, Zhu XM, Lou GL, Ni J: ATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer. J Transl Med 2011;9:211.
25. Li AL, Li HY, Jin BF, Ye QN, Zhou T, Yu XD, Pan X, Man JH, He K, Yu M, Hu MR, Wang J, Yang SC, Shen BF, Zhang XM: A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem 2004;279:49251-49258.
26. Kaiser A: Translational control of eIF5A in various diseases. Amino Acids 2012;42:679-684.
27. Lee NP, Tsang FH, Shek FH, Mao M, Dai H, Zhang C, Dong S, Guan XY, Poon RT, Luk JM: Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int J Cancer 2010;127:968-976.
28. He LR, Zhao HY, Li BK, Liu YH, Liu MZ, Guan XY, Bian XW, Zeng YX, Xie D: Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. Int J Cancer 2011;129:143-150.
29. Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S: Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010;123:97-108.
30. Rice KL, Izon DJ, Ford J, Boodhoo A, Kees UR, Greene WK: Overexpression of stem cell associated ALDH1A1, a target of the leukemogenic transcription factor TLX1/HOX11, inhibits lymphopoiesis and promotes myelopoiesis in murine hematopoietic progenitors. Leuk Res 2008;32:873-883.
31. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567.
32. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS: Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009;178:48-55.
33. Liang D, Shi Y: Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma. Med Oncol 2012;29:633-639.